GleamWall
中文EN

AZN ASTRAZENECA PLC IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.6%
TTM net income YoY45.3%
TTM EPS YoY45.3%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR46.0%

Margins

Gross margin81.9%
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
EBITDA margin—

Returns

ROE22.9%
ROA9.4%
ROIC (approx.)16.8%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets57.3%
Debt / equity0.57x
Current ratio0.94x
Interest coverage8.11x

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio-4.0%
Payout ratio48.6%
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$58.74B$54.07B
Cost of revenue$10.63B$10.21B
Gross profit$48.11B$43.87B
R&D expense$14.23B$13.58B
SG&A expense$19.93B$19.98B
Operating income$13.74B$10.00B
Interest expense$1.69B$1.74B
Pretax income$12.40B$8.69B
Income tax$2.17B$1.65B
Net income$10.22B$7.04B
EPS (basic)6.604.54
EPS (diluted)6.544.50
Dividends declared per share3.132.97
Weighted avg. shares (diluted)1.56B1.56B
Balance sheet
Cash & equivalents$5.71B$5.49B
Short-term investments$30.00M$166.00M
Receivables$15.18B$12.97B
Inventory$6.56B$5.29B
Current assets$28.72B$25.83B
PP&E, netmay include right-of-use assets (IFRS)$12.96B$10.25B
Goodwill$21.24B$21.02B
Intangibles$37.85B$37.18B
Total assets$114.07B$104.03B
Current liabilities$30.62B$27.87B
Short-term debt$3.10B$2.34B
Long-term debt$24.71B$26.51B
Total debt$27.82B$28.84B
Total liabilities$65.36B$63.16B
Shareholders' equity$48.67B$40.79B
Net debt$22.11B$23.36B
Cash flow statement
Operating cash flow$14.57B$11.86B
Capital expenditure$2.81B$1.92B
Free cash flow$11.77B$9.94B
Investing cash flow-$6.81B-$7.98B
Financing cash flow-$7.54B-$4.00B
Stock-based compensation$719.00M$660.00M
Dividends paid$4.97B$4.63B
Share buybacks$521.00M$81.00M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.